5 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
Follow CK0238273: new trials by email Literature Review of CK0238273 trials Research Report on CK0238273
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-01-16 |
| Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer ispinesib - Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2006-05-01 | 2013-06-05 |
| SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel ispinesib, pharmacological study, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2005-04-01 | 2013-01-25 |
| SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer ispinesib, laboratory biomarker analysis, pharmacological study - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2005-01-01 | 2017-03-06 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes ispinesib, laboratory biomarker analysis, pharmacological study - Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-12-01 | 2013-01-11 |
| SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma ispinesib, laboratory biomarker analysis, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 | Terminated | National Cancer Institute (NCI) | 31 | 2004-11-01 | 2013-01-14 |
Burkitt Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Astrocytoma (1) · Blast Crisis (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Congenital Abnormalities (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Familial ependymoma (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Megakaryoblastic, Acute (1)
National Cancer Institute (NCI) (6)
United States (5) · Canada (1)
Brenda Cooper (1) · Eric Winquist (1) · Patricia LoRusso (1) · Richard Sills (1) · Tomasz Beer (1) · Walter Stadler (1)
N01CM62201 (1), N01CM62203 (1), U01CA062487 (1), U01CA062502 (1), U01CA062505 (1), U01CA097452 (1), U10CA032102 (1)